The pathogenesis of malignant ascites

Peritoneal Carcinomatosis: A Multidisciplinary Approach

Volumn , Issue , 2007, Pages 109-118

  Tamsma, Jouke T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASCITES; BLOOD FLOW; CAPILLARY; CARCINOMA; HISTOLOGY; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PERITONEUM; PERITONEUM TUMOR; PHYSIOLOGY; REVIEW; VASCULARIZATION;

ASCITES; CAPILLARIES; CARCINOMA; HUMANS; PERITONEAL NEOPLASMS; PERITONEUM; REGIONAL BLOOD FLOW;

EID: 34548445119     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48993-3_6     Document Type: Chapter

References (38)

1. Gotloib L, Shostak A (1990) The functional anatomy of the peritoneum as a dialyzing membrane. In: Twardowski ZJ, Nolph KD, Khanna R, editors. Contempory issues in Nephrology vol 22. Peritoneal Dialysis: new concepts and applications. New York: Churchill Livingstone, 1-29
2. Nolph KD, Miller F, Rubin J, Popovich R (1980) New directions in peritoneal dialysis concepts and applications. Kidney Int Suppl 10:S111-S116
3. Renkin EM (1986) Some consequences of capillary permeability to macro-molecules: Starling's hypothesis reconsidered. Am J Physiol 250 (5Pt2): H706-H710
4. Grega GJ, Adamski SW, Dobbins DE (1986) Physiological and pharmacological evidence for the regulation of permeability. Fed Proc 45(2):96-100
5. Gotloib L, Digenis GE, Rabinovich S, et al (1983) Ultrastructure of normal rabbit mesentery. Nephron 34(4):248-255
6. Lifshitz S (1982) Ascites, pathophysiology and control measures. Int J Radiat Oncol Biol Phys 8(8):1423-1426
7. Allen L (1931) Volume and pressure changes in terminal lymphatics. Am J Physiol 123:3
8. Guyton AC (1963) A concept of negative interstitial pressure based on pressures in implanted perforated capsules. Circ Res 12:399
9. Zink J, Greenway CV (1977) Control of ascites absorption in anesthetized cats: effects of intraperitoneal pressure, protein, and furosemide diuresis. Gas-troenterology 73(5):1119-1124
10. Casley-Smith JR (1978) A fine ultrastructural study of variations in protein concentration in lacteals during compression and relaxation. Lymphology 12:59-65
11. Shasby DM, Shasby SS (1985) Active transendothelial transport of albumin. Interstitium to lumen. Circ Res 57(6):903-908
12. Runyon BA, Hoefs JC, Morgan TR (1988) Ascitic fluid analysis in malignancy-related ascites. Hepatology 8(5):1104-1109
13. Salerno F, Restelli B, Incerti P, et al (1990) Utility of ascitic fluid analysis in patients with malignancy-related ascites. Scand J Gastroenterol 25(3):251-256
14. Jungst D, Xie Y, Gerbes AL (1992) Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Increased ascites to serum relation of proteins and lipoproteins in patients with peritoneal carcinomatosis as compared to patients with cirrhosis of the liver. J Hepatol 14(2-3):244-248
15. Mactier RA (1990) Kinetics of ultrafiltration with glucose and alternative osmotic agents. In: Twardowski ZJ, Nolph KD, Khanna R, editors. Contemporary issues in nephrology. Peritoneal dialysis, new concepts and applications. New York: Churchill Livingstone, 29-52
16. Fastaia J, Dumont AE (1976) Pathogenesis of ascites in mice with peritoneal carcinomatosis. J Natl Cancer Inst 56(3):547-550
17. Feldman GB, Knapp RC, Order SE, Hellman S (1972) The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 32(8):1663-1666
18. Coates G, Bush RS, Aspin N (1973) A study of ascites using lymphoscinti-graphy with 99m Tc-sulfur colloid. Radiology 107(3):577-583
19. Bronskill MJ, Bush RS, Ege GN (1977) A quantitative measurement of peritoneal drainage in malignant ascites. Cancer 40(5):2375-2380
20. Hirabayashi K, Graham J (1970) Genesis of ascites in ovarian cancer. Am J Obstet Gynecol 106(4):492-497
21. Rose BD, Post TW (2001) Edematous states. In: Rose BD, Post TW (eds). Clinical physiology of acid-base and electrolyte disorders. New York, NY: McGraw-Hill, 478-534
22. Heuser LS, Taylor SH, Folkman J (1984) Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis. J Surg Res 36(3):244-250
23. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 86(3):353-364
24. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9-22
25. Senger DR, Galli SJ, Dvorak AM, et al (1983) Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983-985
26. Nagy JA, Masse EM, Herzberg KT, et al (1995) Pathogenesis of ascites tumour growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55(2):360-368
27. Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumour cell lines. Cancer Res 46(11):5629-5632
28. Yamamoto S, Konishi I, Mandai M, et al (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76(9):1221-1227
29. Barton DP, Cai A, Wendt K, Young M, et al (1997) Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 3(9):1579-1586
30. Zebrowski BK, Liu W, Ramirez K, et al (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6(4):373-378
31. Kraft A, Weindel K, Ochs A, et al (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85(1):178-187
32. Santin AD, Hermonat PL, Ravaggi A, et al (1999) Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 20(3):177-181
33. Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153(4):1249-1256
34. Luo JC, Toyoda M, Shibuya M (1998) Differential inhibition of fluid accumulation and tumour growth in two mouse ascites tumours by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58(12):2594-2600
35. Schlaeppi JM, Wood JM (1999) Targeting vascular endothelial growth factor (VEGF) for anti-tumour therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 18(4):473-481
36. Xu L, Yoneda J, Herrera C, et al (2000) Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibi-tor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16(3):445-454
37. Stoelcker B, Echtenacher B, Weich HA, et al (2000) VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res 20(5):511-517
38. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF (1995) Pathogenesis of ascites tumour growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 55(2):376-385